Jeffrey M. Jonas - Nov 28, 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Director
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Jeffrey M. Jonas
Stock symbol
SAGE
Transactions as of
Nov 28, 2023
Transactions value $
-$75,827
Form type
4
Date filed
11/30/2023, 04:04 PM
Previous filing
Sep 5, 2023
Next filing
Mar 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +10K +8.2% $0.00 132K Nov 28, 2023 Direct F1
transaction SAGE Common Stock Tax liability -$75.8K -3.94K -2.98% $19.27 128K Nov 28, 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 25, 2020, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 25,000 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on November 28, 2023, resulting in the vesting of the PSUs as to 10,000 shares.